The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Lung Complications Closely Entwined with Rheumatologic Diseases

Lung Complications Closely Entwined with Rheumatologic Diseases

September 8, 2016 • By Larry Beresford

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Van Selby, MD, assistant professor of medicine in cardiology at UCSF who works frequently with rheumatologists for patients who have PH, offered additional perspectives on PH and PAH during the lung disease panel at CRA. “Sometimes we use these two terms interchangeably, but it’s important to know which is which. Get familiar with the WHO classification of PH,” he urged attendees. Patients with PH should be referred to someone who has experience treating the condition, whether pulmonologist or cardiologist, Dr. Selby said. Some cardiologists may not be comfortable with it, “but we work closely with rheumatologists all the time for co-management of PAH in systemic sclerosis and other kinds of connective tissue diseases.”

You Might Also Like
  • Tackle Tricky Lung Complications in Connective Tissue Disease
  • When Interstitial Lung Disease and Connective Tissue Disorder Intersect in Rheumatology Patients
  • The ACR’s State-of-the-Art Clinical Symposium: Patients with Scleroderma, Lung Disease May Benefit from Aggressive Therapy
Explore This Issue
September 2016
Also By This Author
  • Non-Radiographic Axial Spondyloarthritis Recognized with ICD-10 Code

Supportive therapy is also critical for these patients, including exercise. “Have patients start out easy and watch closely for chest pain, dizziness or fatigue. Cardiac or pulmonary rehabilitation programs where they are closely monitored are also helpful.” Other supportive measures include diuretics, digoxin, supplemental oxygen, oral anticoagulants and iron supplementation.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

In terms of treatment for CTD-related PAH, an upfront two-drug strategy demonstrated superiority in the huge AMBITION trial comparing initial combination versus monotherapy with tadalafil and ambrisentan, Dr. Selby said.6 “That was a game changer for me and for the pulmonary hypertension community. People are now even studying initial therapy with more than two drugs. The idea is to hit it hard, as early as possible.” This includes treatment of PAH associated with systemic sclerosis, which can be hard to treat. “The last decade has seen many new medications approved for the treatment of PAH. The guidelines are still trying to find the optimal initial approach for each patient.”

Ultimately, once lung function drops below a certain level, lung transplant may be the only long-term treatment option for some of these patients. The speakers encouraged early referral to a transplant center to get patients assessed and enrolled on the transplant list before their condition is too far advanced.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Larry Beresford is an Oakland, Calif.-based freelance medical journalist.

References

  1. Tashkin DP, Roth MD, Clements PJ, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): A randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016 Jul 25. pii: S2213–S2600(16)30152–30157. Epub ahead of print.
  2. King TE, Brandford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014 May 29;370(22):2083–2092.
  3. Richeldi L, duBois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014 May 29;370(22):2071–2082.
  4. Simonneau G, Robbins I, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2009 Jun 30;54(1 Suppl):S43–S54.
  5. Badesch DB, Raskob GE, Elliott CG, et al. Pulmonary arterial hypertension: Baseline characteristics from the REVEAL Registry. Chest. 2010 Feb;137(2):376–387.
  6. Galie N, Barbera JA, Adaani EF, et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med. 2015 Aug 27;373(9):834–844.

Pages: 1 2 3 4 5 | Single Page

Filed Under: Conditions Tagged With: California Rheumatology Alliance 2016, lung, patient care, Research, Rheumatic Disease, rheumatologist, TreatmentIssue: September 2016

You Might Also Like:
  • Tackle Tricky Lung Complications in Connective Tissue Disease
  • When Interstitial Lung Disease and Connective Tissue Disorder Intersect in Rheumatology Patients
  • The ACR’s State-of-the-Art Clinical Symposium: Patients with Scleroderma, Lung Disease May Benefit from Aggressive Therapy
  • What Rheumatologists Need to Know about Diagnosing and Managing Interstitial Lung Disease (ILD)

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.